Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne
Part of paid clinical trials in Tempe, Arizona.
- Sponsor
- Sagimet Biosciences Inc.
- Study ID
- NCT06989840
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Acne
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Accepted
Interventions
- TVB-3567 — DRUGOrally administered capsule
- Placebo — DRUGOrally administered capsule
Study Details
This is a 4-part study. Part A will be a randomized, double-blind, placebo-controlled investigation of single ascending doses (SAD) to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) biomarkers of TVB-3567 administered orally in healthy participants. Part B will be a randomized, open-label, 2-way crossover investigation to assess the effect of food on a single dose TVB-3567 administered orally in healthy participants. Parts C and D will be randomized, double-blind, placebo-controlled investigations of multiple ascending doses (MAD) to assess the safety, tolerability, PK, and PD/biomarkers of TVB-3567 administered orally in healthy participants without and with moderate to severe acne, respectively.
Key Dates
- Start date
- Jun 3, 2025
- Status verified
- Jun 2026
- Primary completion
- Jan 31, 2027
- Completion
- Jan 31, 2027
Study Design
- Enrollment
- 128 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Part A (SAD in Healthy Participants)
- Experimental: Part B (Food Effect)
- Experimental: Part C (MAD in Healthy Participants)
- Experimental: Part D (MAD in Acne Participants)
Primary Outcome Measure
Part A - Incidence of adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: Baseline to 7 to 8 days after dosing ]
Central Contacts
- Study Director(650) 561-8600
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Celerion, Inc. | Tempe | Arizona | 85283 | - |
Find similar trials in Tempe, AZ
Related Studies
- Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe AcnePHASE1/PHASE2 · Recruiting · Sanofi Pasteur, a Sanofi Company · Scottsdale, Arizona
- The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic DermatitisRecruiting · Integrative Skin Science and Research · Sacramento, California
- A Full Face Study to Evaluate the Efficacy of Dermapen 4™ Microneedling Device in Addition with MG-CLR Serum for Acne Treatment Over 12 Weeks.PHASE2/PHASE3 · Not Yet Recruiting · Equipmed USA LLC · Birmingham, Alabama
- AVAVA MIRIA General UseRecruiting · AVAVA, Inc. · Waltham, Massachusetts